Illumina Settles Icahn Partners Lawsuit Over GRAIL Acquisition With No Payment
The genomics company has reached a settlement with activist investor Carl Icahn's entities to dismiss litigation challenging its $8 billion GRAIL acquisition, though related derivative suits continue.
Settlement Resolves Icahn Challenge
Illumina disclosed on August 7 that it has entered into a settlement agreement with Icahn Partners LP and affiliated entities to dismiss litigation challenging the company's controversial acquisition of GRAIL, Inc., with the settlement requiring no payment from any party.
The Release Agreement, effective August 21, 2025, resolves the lawsuit captioned Icahn Partners LP, et al., v. Francis DeSouza, et al. in Delaware's Court of Chancery (8-K filing, 2026-08-07). Under the settlement terms, the action "shall be dismissed with prejudice as to the Plaintiffs only and without prejudice to any other Illumina stockholders" in exchange for mutual releases (8-K filing, 2026-08-07).
The defendants—including former CEO Francis DeSouza and board members John Thompson, Frances Arnold, Caroline Dorsa, Robert Epstein, Scott Gottlieb, Gary Guthart, Philip Schiller, and Susan Siegel—"continue to deny each and all of the claims and contentions alleged by plaintiffs in the litigation and expressly deny any fault, wrongdoing or liability" (8-K filing, 2026-08-07). The parties agreed to the settlement "solely to avoid the burden, expense and uncertainty of further litigation" (8-K filing, 2026-08-07).
Background of the GRAIL Litigation
The lawsuit, filed in October 2023, challenged Illumina's approximately $8 billion reacquisition of GRAIL, announced in September 2020. The transaction faced regulatory scrutiny from both the U.S. Federal Trade Commission and European regulators. Plaintiffs brought both direct and derivative claims alleging breach of fiduciary duties by Illumina's directors.
The complaint sought extensive relief, including supplemental disclosures, removal of directors from the board, and damages. The litigation faced significant procedural hurdles early on when the Delaware Court of Chancery struck portions of the complaint in January 2024, finding that it "included (under seal) confidential information protected by the attorney-client privilege that was improperly provided to Plaintiffs" (8-K filing, 2026-08-07).
In December 2023, Illumina announced it would divest GRAIL. In September 2024, the European Court of Justice ruled that the European Commission "never had jurisdiction to review the GRAIL Acquisition," prompting the EC to withdraw all decisions related to the merger, including fines imposed on Illumina (8-K filing, 2026-08-07).
Related Cases Continue
The settlement explicitly preserves the rights of other Illumina shareholders. Three related derivative actions remain pending in Delaware Chancery Court, filed by The City of Omaha Police & Firefighters Retirement System, City of Roseville General Employees Retirement System, and The Pavers & Road Builders Benefit Funds, all asserting similar breach of fiduciary duty claims.
A motion to dismiss these derivative actions is currently pending, with defendants arguing the claims are entitled to business judgment protection and that plaintiffs fail to identify violations of law, particularly given the European court's jurisdictional ruling.
The Delaware Court of Chancery will hold a hearing on November 2, 2026, at 1:30 p.m. Eastern time to approve the proposed dismissal (8-K filing, 2026-08-07). MarginX data shows recent insider activity at Illumina, including sales by Keith A. Meister totaling 130,125 shares and an award of 5,254 shares to Michael C. Sullivan.
This article was generated by MarginX from the 8-K filing on 2026-08-07. It is not investment advice.